Before taking Enasidenib(Idhifa)

This section highlights critical warnings and monitoring requirements for safe use.

Warnings and Monitoring

A boxed warning emphasizes the risk of differentiation syndrome, which can occur early during treatment and requires prompt intervention with corticosteroids and hemodynamic monitoring. IDHIFA can cause fetal harm, necessitating effective non-hormonal contraception in patients of reproductive potential. Close monitoring of blood counts and chemistries is essential, particularly during the first three months of therapy, to detect conditions like leukocytosis and tumor lysis syndrome. Numerous drug interactions require caution.